Clinical Trial Detail

NCT ID NCT03200587
Title Cabometyx and Avelumab in Patients With Metastatic Renal Cell Carcinoma (mRCC)
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors University of Utah
Indications

renal cell carcinoma

Therapies

Avelumab + Cabozantinib

Age Groups: senior adult

No variant requirements are available.